



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

LLC0424

Cat. No.:	HY-161574
Molecular Formula:	C ₄₅ H ₄₁ N ₇ O ₉
Molecular Weight:	823.85
Target:	PROTACs; Histone Methyltransferase
Pathway:	PROTAC; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	LLC0424 is a potent and selective cereblon-based PROTAC nuclear receptor-binding SET domain-containing 2 (NSD2) degrader. LLC0424 effectively degraded NSD2 with a DC ₅₀ of 20 nM in RPMI-8402 cells. LLC0424 selectively induces NSD2 degradation in a cereblon- and proteasome-dependent fashion. (Blue: CRBN ligand (HY-14658), Black: linker (HY-40002); Pink: NSD2 inhibitor (HY-161575)) ^[1] .																	
IC₅₀ & Target	Cereblon	NSD2 20 nM (DC50)																
In Vitro	<p>In SEM and RPMI-8402 cells, LLC0424 dose-dependently suppresses the growth of these two cell lines, with IC₅₀ values of 3.56 μM and 0.56 μM respectively^[1].</p> <p>LLC0424 (0.001 μM-10 μM; 1 h-24 h) induces NSD2 degradation in a concentration- and time-dependent manner, and induces NSD2 degradation in a CRBN- and proteasome-dependent manner. LLC0424 also leads to downregulation of H3K36Me2^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[1]</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Cell Line:</td> <td>SEM or RPMI-8402 cells</td> </tr> <tr> <td>Concentration:</td> <td>5 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>9 days (every 4 days)</td> </tr> <tr> <td>Result:</td> <td>Significantly inhibited the growth of SEM and RPMI-8402 cells.</td> </tr> </table> <p>Western Blot Analysis^[1]</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Cell Line:</td> <td>RPMI-8402 cells</td> </tr> <tr> <td>Concentration:</td> <td>0.001 μM, 0.01 μM, 0.1 μM, 1 μM, and 10 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h</td> </tr> <tr> <td>Result:</td> <td>Reduced the protein level of both NSD2 isoforms in a concentration- and time-dependent manner.</td> </tr> </table>		Cell Line:	SEM or RPMI-8402 cells	Concentration:	5 μM	Incubation Time:	9 days (every 4 days)	Result:	Significantly inhibited the growth of SEM and RPMI-8402 cells.	Cell Line:	RPMI-8402 cells	Concentration:	0.001 μM, 0.01 μM, 0.1 μM, 1 μM, and 10 μM	Incubation Time:	1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h	Result:	Reduced the protein level of both NSD2 isoforms in a concentration- and time-dependent manner.
Cell Line:	SEM or RPMI-8402 cells																	
Concentration:	5 μM																	
Incubation Time:	9 days (every 4 days)																	
Result:	Significantly inhibited the growth of SEM and RPMI-8402 cells.																	
Cell Line:	RPMI-8402 cells																	
Concentration:	0.001 μM, 0.01 μM, 0.1 μM, 1 μM, and 10 μM																	
Incubation Time:	1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h																	
Result:	Reduced the protein level of both NSD2 isoforms in a concentration- and time-dependent manner.																	

In Vivo

LLC0424 (60 mg/kg; iv or ip; for 5 consecutive days) shows potent NSD2 degradation in vivo^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-8 weeks old male CB17 severe combined immunodeficiency (SCID) mice injected with 22RV1 cells were injected ^[1]
Dosage:	60 mg/kg
Administration:	Intravenous injection or intraperitoneal injection; for five consecutive days
Result:	Significantly downregulated the protein levels of NSD2.

REFERENCES

[1]. Lianchao Liu, et al. Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degradator. J Med Chem. 2024 May 9;67(9):6938-6951.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA